The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services, is seeking a research contract to investigate Transthyretin (TTR) variants in sickle cell disease severity using Olink Proteomics. The procurement falls under the Testing Laboratories and Services NAICS category and specifically targets reference laboratory testing services. The primary objective appears to be a scientific research project focused on understanding genetic and proteomic factors influencing sickle cell disease progression. While specific evaluation criteria are not detailed in the pre-solicitation notice, typical federal research contracts often assess scientific merit, research team qualifications, methodological approach, and potential impact of the proposed study. The opportunity was posted on January 16, 2025, with responses due by January 23, 2025, indicating a relatively tight timeframe for potential bidders to prepare and submit their proposals.

The pre-solicitation notice indicates no specific set-aside designations, suggesting the opportunity is open to a broad range of qualified laboratory and research organizations. No incumbent contractor information is provided in the available documentation. The contract is classified under the Testing Laboratories and Services NAICS code 541380, which typically involves specialized scientific research and diagnostic services. While exact award values are not specified, federal research contracts in this domain can range from tens of thousands to several hundred thousand dollars depending on scope and complexity. The research appears to be a targeted, focused investigation into the proteomic aspects of sickle cell disease, likely requiring advanced laboratory capabilities, specialized proteomics expertise, and sophisticated genetic analysis techniques.

Investigating TTR Variants in Sickle Cell Disease Severity Using Olink Proteomi

Opportunity facts

About this opportunity

Notice text

Work this opportunity